Last reviewed · How we verify
NCT05922111
Cervical Ripening Balloon for 12 Hours vs. 1 Hour.
NA trial testing cervical ripening balloon for one hour in Induction of Labor in 164 participants. Not yet recruiting.
31 December 2025
Quick facts
| Lead sponsor | Rambam Health Care Campus |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 164 |
| Start date | 1 August 2023 |
| Primary completion | 31 December 2025 |
| Estimated completion | 30 June 2026 |
Drugs / interventions tested
- cervical ripening balloon for one hour
- cervical ripening balloon for twelve hours
Conditions studied
- Induction of Labor — all drugs for Induction of Labor →
Sponsor
Rambam Health Care Campus — full company profile →
Who can join
Adults 18 to 45, female only, with Induction of Labor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is a comparison of induction of labor with a cervical ripening balloon left in place for one hour compared to twelve hours. The primary outcome is time to delivery. Women admitted for induction of labor will be recruited and randomized to either a cervical ripening balloon for one hour or twelve hours. the management of delivery after the extraction of the balloon will be left to the discretion of the attending physician.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05922111
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Induction of Labor
Currently open trials in the same condition.
- NCT06803992 — Induction of Labor - Comparison Propess With Prostaglandin E2 Vaginal Gel and Balloon Catheter · Phase 4 · recruiting
Other Rambam Health Care Campus trials
Trials by the same sponsor.
- NCT07384013 — Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs · NA · recruiting
- NCT06688253 — Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis · Phase 4 · not yet recruiting
- NCT06235749 — Administration Of Calcium Gluconate for The Reduction of Blood Loss During Elective Cesarean Delivery · NA · recruiting
- NCT06622902 — Influence of Flow Rate Change on CO2 Levels During High Flow Nasal Ventilation (HFNV) in Preterm Infants. · NA · recruiting
- NCT05812547 — A Novel Device for Gestational Diabetes Control · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05922111 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rambam Health Care Campus
- Last refreshed: 28 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05922111.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing